Canary Speech
Artificial intelligence software for the healthcare industry to detect neurological diseases through voice analysis.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
* | $13.0m | Series A | |
| Total Funding | 000k | ||
Related Content
Canary Speech was co-founded by Henry O'Connell and Jeff Adams. O'Connell has a background of over 25 years in the medical device industry, while Adams is a recognized figure in speech and language technology.
The company has developed a patented vocal biomarker technology that uses artificial intelligence to analyze speech patterns and detect various health conditions. This technology is designed to be language-agnostic and can be used on any device with a microphone, including smartphones and computers. The analysis is done in near real-time, providing immediate results from as little as 20 seconds of speech.
Canary Speech's primary market is the healthcare industry, where its technology can be used to screen for cognitive and behavioral conditions such as Alzheimer's, dementia, depression, and anxiety. The company's business model is based on providing its platform to healthcare providers, who can then use it to assess and monitor their patients. The technology is non-invasive and can be used to conduct analysis anytime and anywhere, making it a convenient and stress-free option for patients.
Keywords: vocal biomarkers, speech analysis, AI, healthcare technology, cognitive health, behavioral health, mental health screening, neurological disorders, real-time analysis, digital health